Best Practice & Research Clinical Haematology最新文献

Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation 供体特异性 HLA 抗体与造血细胞移植的相关性

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101576

引用次数: 0

From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation 从克隆到免疫肽组：造血细胞移植中允许的 HLA-DP 错配特征研究的新进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101575

{"title":"From clones to immunopeptidomes: New developments in the characterization of permissive HLA-DP mismatches in hematopoietic cell transplantation","authors":"","doi":"10.1016/j.beha.2024.101575","DOIUrl":"10.1016/j.beha.2024.101575","url":null,"abstract":"<div><p>Mismatching at the HLA-DPB1 locus occurs frequently in hematopoietic cell transplantation with unrelated donors. Despite this, HLA-DPB1 allelic mismatches have traditionally not been considered in patient-donor matching. A T-cell epitope (TCE) model for the functional assessment of permissive mismatches at this locus has nevertheless been adopted in clinical practice. While initially based on a hierarchical immunogenicity elucidated from allorecognition by T-cell clones isolated from a patient, newer developments in the understanding of this model's biological basis, including a central role for immunopeptidome divergence between mismatched allotypes, have prompted changes in the assignment of permissiveness, providing the opportunity for a more granular evaluation of graft-<em>versus</em>-host disease and relapse risks according to the nature and directionality of permissive mismatches. How these advances impact the assessment of permissiveness at HLA-DPB1 and potentially the intelligent selection of donors according to the main clinical goal for different patients is the subject of the present review.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000410/pdfft?md5=eccbdb3e12a17ab67dc0a72288f21c09&pid=1-s2.0-S1521692624000410-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HLA structure and function in hematopoietic-cell transplantation 造血细胞移植中的 HLA 结构和功能

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-09-01 DOI: 10.1016/j.beha.2024.101564

引用次数: 0

Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy 干扰 KIR 和 NKG2A 免疫检查点轴释放 NK 细胞免疫疗法

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-07-31 DOI: 10.1016/j.beha.2024.101568

{"title":"Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy","authors":"","doi":"10.1016/j.beha.2024.101568","DOIUrl":"10.1016/j.beha.2024.101568","url":null,"abstract":"<div><p>Due to their intrinsic ability to eliminate malignant cells, natural killer (NK) cells emerge as a promising immunotherapy for cancer. While clinical studies have affirmed the safety of NK cell infusions and combination therapies have demonstrated encouraging outcomes in hematological malignancies, the efficacy of NK cell immunotherapeutic interventions remains heterogeneous across patient cohorts. Moreover, the implementation of NK cell immunotherapy in solid tumors presents notable challenges. Interfering with key NK cell inhibitory signaling pathways by targeting inhibitory killer cell immunoglobulin-like receptors (KIRs) and CD94/NK group 2 member A (NKG2A), holds promise for unleashing the full potential of NK cell-based immunotherapy. In this review, we provide an overview of the current approaches for interfering with inhibitory KIR and NKG2A signaling, exploring a selection of the multitude of combination strategies available. We discuss the significance of maintaining the delicate balance between achieving optimal suppression of NK cell inhibition and ensuring effective activation of anti-tumor effector function, while preserving the favorable safety profiles. The consideration of strategies to modulate inhibitory signaling pathways associated with KIR and NKG2A presents promising avenues for enhancing the efficacy of NK cell immunotherapy.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytomegalovirus in haematopoietic cell transplantation - The troll is still there 造血细胞移植中的巨细胞病毒--巨怪依然存在

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-07-26 DOI: 10.1016/j.beha.2024.101565

引用次数: 0

Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease 破译主要组织相容性复合体、肠道微生物组和代谢物在急性移植物抗宿主病发病机制中的作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-07-26 DOI: 10.1016/j.beha.2024.101567

{"title":"Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease","authors":"","doi":"10.1016/j.beha.2024.101567","DOIUrl":"10.1016/j.beha.2024.101567","url":null,"abstract":"<div><p>Allogeneic hematologic stem cell transplantation is a cornerstone in modern hematological treatment, yet its efficacy is compromised by acute Graft-versus-Host Disease. In acute Graft-versus-Host Disease, conditioning regimen induced epithelial damage leads to release of damage and pathogen associated molecular patters which in turns triggers activation of alloreactive donor T cells, ultimately resulting in destruction of healthy tissue. Advances in major histocompatibility complex typing and preclinical studies using tissue specific major histocompatibility complex deletion have illuminated the contributions of both, hematopoietic and non-hematopoietic cells to acute Graft-versus-Host Disease pathophysiology. Concurrently, high-throughput sequencing techniques have enabled researchers to recognize the significant impact of the intestinal microbiome and newly discovered metabolites in the pathophysiology of acute Graft-versus-Host Disease. In this review, we discuss the implications of major histocompatibility complex expression on hematopoietic and non-hematopoietic cells, the effect on the intestinal microbiome and the metabolic alterations that contribute to acute Graft-versus-Host Disease. By combining these findings, we hope to untangle the complexity of acute Graft-versus-Host Disease, ultimately paving the way for the development of novel and more effective treatmen options in patients.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000331/pdfft?md5=c71c173468158c3486a91814049fbdbf&pid=1-s2.0-S1521692624000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141771791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances 异体 "现成 "CAR T 细胞：挑战与进步

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-07-25 DOI: 10.1016/j.beha.2024.101566

{"title":"Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances","authors":"","doi":"10.1016/j.beha.2024.101566","DOIUrl":"10.1016/j.beha.2024.101566","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical efficacy in B cell malignancies and multiple myeloma, leading to the approval of six CAR T cell products by the U.S. Food and Drug Administration (FDA) to date. However, broad application of these autologous (patient-derived) CAR T cells is limited by several factors, including high production costs, inconsistent product quality, contamination of the cell product with malignant cells, manufacturing failure especially in heavily pre-treated patients, and lengthy manufacturing times resulting in subsequent treatment delay. A potential solution to these barriers lies in the use of allogeneic “off-the-shelf” CAR T cells produced from healthy donors. Many efforts are underway to make allogeneic CAR T cells a safe and efficacious therapeutic option. In this review, we will discuss the major challenges that have to be addressed to successfully develop allogeneic CAR T cell therapies, specifically graft-versus-host disease (GVHD) and host-mediated immune rejection of the donor cells. Furthermore, we will summarize approaches that have been utilized to overcome these limitations, focusing on the use of gene editing technologies and strategies employing alternative cell populations as the source for allogeneic CAR T cell production.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141940886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation HLA 分型：造血细胞移植方法和临床影响综述

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-06-01 DOI: 10.1016/j.beha.2024.101562

引用次数: 0

Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT? HLA-E 及其受体是异体肝细胞移植中的免疫检查点还是抗原决定因素？

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-06-01 DOI: 10.1016/j.beha.2024.101560

{"title":"Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?","authors":"","doi":"10.1016/j.beha.2024.101560","DOIUrl":"10.1016/j.beha.2024.101560","url":null,"abstract":"<div><p>Hematopoietic cell transplantation (HCT) represents a potentially curative therapeutic approach for various hematologic and non-hematologic malignancies. Human leukocyte antigen (HLA) matching is still the central selection criterion for HCT donors. Nevertheless, post-transplant complications, in particular graft-versus-host disease (GvHD), relapse of disease and infectious complications, represent a major challenge and contribute significantly to morbidity and mortality. Recently, non-classical HLA class I molecules, especially HLA-E, have gained increasing attention in the context of allogeneic HCT. This review aims to summarize the latest findings on the immunomodulatory role of HLA-E, which serves as a ligand for receptors of the innate and adaptive immune system. In particular, we aim to elucidate how (i) polymorphisms within HLA-E, (ii) the NKG2A/C axis and (iii) the repertoire of peptides presented by HLA-E jointly influence the functionality of immune effector cells. Understanding this intricate network of interactions is crucial as it significantly affects NK and T cell responses and thus clinical outcomes after HCT<strong>.</strong></p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1521692624000264/pdfft?md5=e46f9affe65f1d7070552dcbb0d40e80&pid=1-s2.0-S1521692624000264-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registries and observational databases in haematology 血液学登记和观察数据库

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2024-06-01 DOI: 10.1016/j.beha.2024.101563

引用次数: 0